Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-03-11

AUTHORS

Li Yan, Bing Wang, Yen Lin Chia, Lorin K. Roskos

ABSTRACT

INTRODUCTION: Benralizumab, an interleukin-5 receptor alpha-directed cytolytic anti-eosinophil monoclonal antibody, was recently approved as add-on maintenance treatment for patients aged 12 years and older with uncontrolled asthma with eosinophilic inflammation. METHODS: Pharmacokinetic (PK) data from nine clinical trials for patients with asthma were pooled and analyzed to further characterize the PK of benralizumab and evaluate demographic covariate effects. RESULTS: Population modeling results demonstrated that the PK of benralizumab were dose-proportional across a wide dosage range and were adequately described by a two-compartment model with first-order absorption from the subcutaneous dosing site and a first-order elimination pathway from the central compartment. Following subcutaneous administration, the absorption half-life of benralizumab was 3.54 days, and the absolute bioavailability was 58.9%. Estimated clearance (CL; 0.291 L/day), central volume of distribution (Vc; 3.13 L), and peripheral volume of distribution (Vp; 2.52 L) were typical for therapeutic immunoglobulins. Elimination half-life was approximately 15.5 days for patients with asthma. Age, sex, race, liver function, renal function, baseline blood eosinophil count, anatomic injection site, and commonly used small-molecule drugs had no clinically relevant impact on benralizumab CL. Only body weight and antidrug antibodies (ADAs) were identified as relevant PK covariates. Power parameters (exponent) of body weight on CL, Vc, and Vp were 0.807, 0.803, and 0.528, respectively, and the presence of ADAs increased benralizumab CL by 124%. CONCLUSIONS: Over 5-20 weeks, the PK of benralizumab were dose-proportional across a dosage range of 0.03-3 mg/kg intravenously and 2-200 mg subcutaneously administered every 4 weeks or every 8 weeks (first three doses every 4 weeks). Body weight and ADA status were identified as relevant PK covariates. Baseline eosinophil count, hepatic and renal functions, anatomical subcutaneous injection site, and commonly used small-molecule drugs had no impact on the PK of benralizumab. More... »

PAGES

1-16

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40262-019-00738-4

DOI

http://dx.doi.org/10.1007/s40262-019-00738-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112677704

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30854591


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "MedImmune LLC, South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yan", 
        "givenName": "Li", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "MedImmune LLC, South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Bing", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "MedImmune LLC, South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chia", 
        "givenName": "Yen Lin", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "MedImmune LLC, One MedImmune Way, 20878, Gaithersburg, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Roskos", 
        "givenName": "Lorin K.", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.jaci.2013.05.020", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000784865"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/jaa.s111170", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001959810"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jaci.2010.04.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003494892"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(16)31324-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012580029"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s2213-2600(14)70201-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015028027"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmjopen-2014-005748", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021604667"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ajem.2014.09.036", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022247855"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10928-007-9078-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023091556", 
          "https://doi.org/10.1007/s10928-007-9078-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1208/s12248-012-9367-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031115047", 
          "https://doi.org/10.1208/s12248-012-9367-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/09059180.00004013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031195298"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ddr.10346", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034131964"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(16)31322-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046866897"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jaci.2010.04.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050110387"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1011579109640", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050273756", 
          "https://doi.org/10.1023/a:1011579109640"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/psp4.12160", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053818825"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00001648-200005000-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060138988"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00001648-200005000-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060138988"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00001648-200005000-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060138988"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s2213-2600(17)30190-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085462692"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1703501", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085567589"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cpt.1371", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1111546706"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cpt.1371", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1111546706"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cpt.1371", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1111546706"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cpt.1371", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1111546706"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-03-11", 
    "datePublishedReg": "2019-03-11", 
    "description": "INTRODUCTION: Benralizumab, an interleukin-5 receptor alpha-directed cytolytic anti-eosinophil monoclonal antibody, was recently approved as add-on maintenance treatment for patients aged 12\u00a0years and older with uncontrolled asthma with eosinophilic inflammation.\nMETHODS: Pharmacokinetic (PK) data from nine clinical trials for patients with asthma were pooled and analyzed to further characterize the PK of benralizumab and evaluate demographic covariate effects.\nRESULTS: Population modeling results demonstrated that the PK of benralizumab were dose-proportional across a wide dosage range and were adequately described by a two-compartment model with first-order absorption from the subcutaneous dosing site and a first-order elimination pathway from the central compartment. Following subcutaneous administration, the absorption half-life of benralizumab was 3.54\u00a0days, and the absolute bioavailability was 58.9%. Estimated clearance (CL; 0.291 L/day), central volume of distribution\u00a0(Vc; 3.13\u00a0L), and peripheral volume of distribution (Vp; 2.52\u00a0L) were typical for therapeutic immunoglobulins. Elimination half-life was approximately 15.5\u00a0days for patients with asthma. Age, sex, race, liver function, renal function, baseline blood eosinophil count, anatomic injection site, and commonly used small-molecule drugs had no clinically relevant impact on benralizumab CL. Only body weight and antidrug antibodies (ADAs) were identified as relevant PK covariates. Power parameters (exponent) of body weight on CL, Vc, and Vp were 0.807, 0.803, and 0.528, respectively, and the presence of ADAs increased benralizumab CL by 124%.\nCONCLUSIONS: Over 5-20\u00a0weeks, the PK of benralizumab were dose-proportional across a dosage range of 0.03-3\u00a0mg/kg intravenously and 2-200\u00a0mg subcutaneously administered every 4\u00a0weeks or every 8\u00a0weeks (first three doses every 4\u00a0weeks). Body weight and ADA status were identified as relevant PK covariates. Baseline eosinophil count, hepatic and renal functions, anatomical subcutaneous injection site, and commonly used small-molecule drugs had no impact on the PK of benralizumab.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s40262-019-00738-4", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1085321", 
        "issn": [
          "0312-5963", 
          "1179-1926"
        ], 
        "name": "Clinical Pharmacokinetics", 
        "type": "Periodical"
      }
    ], 
    "name": "Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma", 
    "pagination": "1-16", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "b868aa555fcc4c9ebef388a9039e17a0ef0ecfd8fec76e54dde5c4013eecf5b8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30854591"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7606849"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40262-019-00738-4"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112677704"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40262-019-00738-4", 
      "https://app.dimensions.ai/details/publication/pub.1112677704"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T11:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000355_0000000355/records_53007_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs40262-019-00738-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40262-019-00738-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40262-019-00738-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40262-019-00738-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40262-019-00738-4'


 

This table displays all metadata directly associated to this object as RDF triples.

141 TRIPLES      21 PREDICATES      45 URIs      18 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40262-019-00738-4 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N5c66f900e07847fa90b4d6ecd6247fd3
4 schema:citation sg:pub.10.1007/s10928-007-9078-9
5 sg:pub.10.1023/a:1011579109640
6 sg:pub.10.1208/s12248-012-9367-0
7 https://doi.org/10.1002/cpt.1371
8 https://doi.org/10.1002/ddr.10346
9 https://doi.org/10.1002/psp4.12160
10 https://doi.org/10.1016/j.ajem.2014.09.036
11 https://doi.org/10.1016/j.jaci.2010.04.004
12 https://doi.org/10.1016/j.jaci.2010.04.005
13 https://doi.org/10.1016/j.jaci.2013.05.020
14 https://doi.org/10.1016/s0140-6736(16)31322-8
15 https://doi.org/10.1016/s0140-6736(16)31324-1
16 https://doi.org/10.1016/s2213-2600(14)70201-2
17 https://doi.org/10.1016/s2213-2600(17)30190-x
18 https://doi.org/10.1056/nejmoa1703501
19 https://doi.org/10.1097/00001648-200005000-00006
20 https://doi.org/10.1136/bmjopen-2014-005748
21 https://doi.org/10.1183/09059180.00004013
22 https://doi.org/10.2147/jaa.s111170
23 schema:datePublished 2019-03-11
24 schema:datePublishedReg 2019-03-11
25 schema:description INTRODUCTION: Benralizumab, an interleukin-5 receptor alpha-directed cytolytic anti-eosinophil monoclonal antibody, was recently approved as add-on maintenance treatment for patients aged 12 years and older with uncontrolled asthma with eosinophilic inflammation. METHODS: Pharmacokinetic (PK) data from nine clinical trials for patients with asthma were pooled and analyzed to further characterize the PK of benralizumab and evaluate demographic covariate effects. RESULTS: Population modeling results demonstrated that the PK of benralizumab were dose-proportional across a wide dosage range and were adequately described by a two-compartment model with first-order absorption from the subcutaneous dosing site and a first-order elimination pathway from the central compartment. Following subcutaneous administration, the absorption half-life of benralizumab was 3.54 days, and the absolute bioavailability was 58.9%. Estimated clearance (CL; 0.291 L/day), central volume of distribution (Vc; 3.13 L), and peripheral volume of distribution (Vp; 2.52 L) were typical for therapeutic immunoglobulins. Elimination half-life was approximately 15.5 days for patients with asthma. Age, sex, race, liver function, renal function, baseline blood eosinophil count, anatomic injection site, and commonly used small-molecule drugs had no clinically relevant impact on benralizumab CL. Only body weight and antidrug antibodies (ADAs) were identified as relevant PK covariates. Power parameters (exponent) of body weight on CL, Vc, and Vp were 0.807, 0.803, and 0.528, respectively, and the presence of ADAs increased benralizumab CL by 124%. CONCLUSIONS: Over 5-20 weeks, the PK of benralizumab were dose-proportional across a dosage range of 0.03-3 mg/kg intravenously and 2-200 mg subcutaneously administered every 4 weeks or every 8 weeks (first three doses every 4 weeks). Body weight and ADA status were identified as relevant PK covariates. Baseline eosinophil count, hepatic and renal functions, anatomical subcutaneous injection site, and commonly used small-molecule drugs had no impact on the PK of benralizumab.
26 schema:genre research_article
27 schema:inLanguage en
28 schema:isAccessibleForFree false
29 schema:isPartOf sg:journal.1085321
30 schema:name Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma
31 schema:pagination 1-16
32 schema:productId N16856d4d8f61446299a91eba26970e29
33 Na4c33bd2764f4205bc151247cb73835d
34 Nca9a8000af2d4d27b8eaa919c817f9c0
35 Nd67909db30df40ea8ebfb9d429cf3607
36 Ne58550b4539345438720b362b036c1d1
37 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112677704
38 https://doi.org/10.1007/s40262-019-00738-4
39 schema:sdDatePublished 2019-04-11T11:24
40 schema:sdLicense https://scigraph.springernature.com/explorer/license/
41 schema:sdPublisher N6c089d6fb44a48598284734de677bd6c
42 schema:url https://link.springer.com/10.1007%2Fs40262-019-00738-4
43 sgo:license sg:explorer/license/
44 sgo:sdDataset articles
45 rdf:type schema:ScholarlyArticle
46 N0d89f4be722644aa986aa5e201ff3962 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
47 schema:familyName Wang
48 schema:givenName Bing
49 rdf:type schema:Person
50 N16856d4d8f61446299a91eba26970e29 schema:name nlm_unique_id
51 schema:value 7606849
52 rdf:type schema:PropertyValue
53 N268ba1a98cc44d4ba2d29b3b3c993f15 rdf:first N0d89f4be722644aa986aa5e201ff3962
54 rdf:rest N3844f725cb0d49379985e4844a6f7a5f
55 N36fa82f06a82427a98f29988145bd5eb rdf:first N495127c40eca426597df9d424c7601ed
56 rdf:rest rdf:nil
57 N3844f725cb0d49379985e4844a6f7a5f rdf:first N7420f1f7c4b34ba7b93e4f92a65c3857
58 rdf:rest N36fa82f06a82427a98f29988145bd5eb
59 N495127c40eca426597df9d424c7601ed schema:affiliation https://www.grid.ac/institutes/grid.418152.b
60 schema:familyName Roskos
61 schema:givenName Lorin K.
62 rdf:type schema:Person
63 N5c66f900e07847fa90b4d6ecd6247fd3 rdf:first N7a7b496ac4b740689720559eadc80e34
64 rdf:rest N268ba1a98cc44d4ba2d29b3b3c993f15
65 N6c089d6fb44a48598284734de677bd6c schema:name Springer Nature - SN SciGraph project
66 rdf:type schema:Organization
67 N7420f1f7c4b34ba7b93e4f92a65c3857 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
68 schema:familyName Chia
69 schema:givenName Yen Lin
70 rdf:type schema:Person
71 N7a7b496ac4b740689720559eadc80e34 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
72 schema:familyName Yan
73 schema:givenName Li
74 rdf:type schema:Person
75 Na4c33bd2764f4205bc151247cb73835d schema:name readcube_id
76 schema:value b868aa555fcc4c9ebef388a9039e17a0ef0ecfd8fec76e54dde5c4013eecf5b8
77 rdf:type schema:PropertyValue
78 Nca9a8000af2d4d27b8eaa919c817f9c0 schema:name doi
79 schema:value 10.1007/s40262-019-00738-4
80 rdf:type schema:PropertyValue
81 Nd67909db30df40ea8ebfb9d429cf3607 schema:name pubmed_id
82 schema:value 30854591
83 rdf:type schema:PropertyValue
84 Ne58550b4539345438720b362b036c1d1 schema:name dimensions_id
85 schema:value pub.1112677704
86 rdf:type schema:PropertyValue
87 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
88 schema:name Medical and Health Sciences
89 rdf:type schema:DefinedTerm
90 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
91 schema:name Clinical Sciences
92 rdf:type schema:DefinedTerm
93 sg:journal.1085321 schema:issn 0312-5963
94 1179-1926
95 schema:name Clinical Pharmacokinetics
96 rdf:type schema:Periodical
97 sg:pub.10.1007/s10928-007-9078-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023091556
98 https://doi.org/10.1007/s10928-007-9078-9
99 rdf:type schema:CreativeWork
100 sg:pub.10.1023/a:1011579109640 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050273756
101 https://doi.org/10.1023/a:1011579109640
102 rdf:type schema:CreativeWork
103 sg:pub.10.1208/s12248-012-9367-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031115047
104 https://doi.org/10.1208/s12248-012-9367-0
105 rdf:type schema:CreativeWork
106 https://doi.org/10.1002/cpt.1371 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111546706
107 rdf:type schema:CreativeWork
108 https://doi.org/10.1002/ddr.10346 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034131964
109 rdf:type schema:CreativeWork
110 https://doi.org/10.1002/psp4.12160 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053818825
111 rdf:type schema:CreativeWork
112 https://doi.org/10.1016/j.ajem.2014.09.036 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022247855
113 rdf:type schema:CreativeWork
114 https://doi.org/10.1016/j.jaci.2010.04.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003494892
115 rdf:type schema:CreativeWork
116 https://doi.org/10.1016/j.jaci.2010.04.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050110387
117 rdf:type schema:CreativeWork
118 https://doi.org/10.1016/j.jaci.2013.05.020 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000784865
119 rdf:type schema:CreativeWork
120 https://doi.org/10.1016/s0140-6736(16)31322-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046866897
121 rdf:type schema:CreativeWork
122 https://doi.org/10.1016/s0140-6736(16)31324-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012580029
123 rdf:type schema:CreativeWork
124 https://doi.org/10.1016/s2213-2600(14)70201-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015028027
125 rdf:type schema:CreativeWork
126 https://doi.org/10.1016/s2213-2600(17)30190-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1085462692
127 rdf:type schema:CreativeWork
128 https://doi.org/10.1056/nejmoa1703501 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085567589
129 rdf:type schema:CreativeWork
130 https://doi.org/10.1097/00001648-200005000-00006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1060138988
131 rdf:type schema:CreativeWork
132 https://doi.org/10.1136/bmjopen-2014-005748 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021604667
133 rdf:type schema:CreativeWork
134 https://doi.org/10.1183/09059180.00004013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031195298
135 rdf:type schema:CreativeWork
136 https://doi.org/10.2147/jaa.s111170 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001959810
137 rdf:type schema:CreativeWork
138 https://www.grid.ac/institutes/grid.418152.b schema:alternateName AstraZeneca (United States)
139 schema:name MedImmune LLC, One MedImmune Way, 20878, Gaithersburg, MD, USA
140 MedImmune LLC, South San Francisco, CA, USA
141 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...